Kymera TherapeuticsKYMR
KYMR
About: Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Employees: 208
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
19% more call options, than puts
Call options by funds: $7.84M | Put options by funds: $6.59M
11% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 57
1.38% more ownership
Funds ownership: 110.73% [Q4 2024] → 112.12% (+1.38%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 9 (+0) [Q1 2025]
4% less funds holding
Funds holding: 180 [Q4 2024] → 172 (-8) [Q1 2025]
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
31% less capital invested
Capital invested by funds: $2.89B [Q4 2024] → $2B (-$890M) [Q1 2025]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$44
1%
downside
Avg. target
$59
33%
upside
High target
$79
78%
upside
10 analyst ratings
9 positive
90%
1 neutral
10%
0 negative
0%
Oppenheimer Jeff Jones | 19%upside $53 | Outperform Maintained | 27 Jun 2025 |
Wells Fargo Derek Archila | 19%upside $53 | Overweight Maintained | 26 Jun 2025 |
HC Wainwright & Co. Andrew Fein | 35%upside $60 | Buy Maintained | 26 Jun 2025 |
B. Riley Securities Kalpit Patel | 35%upside $60 | Buy Upgraded | 3 Jun 2025 |
Morgan Stanley James Quigley | 78%upside $79 | Overweight Upgraded | 3 Jun 2025 |
Financial journalist opinion
Based on 8 articles about KYMR published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $44.00 per share and the pre-funded warrants are being sold at a public offering price of $43.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 855,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $250.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters' option to purchase additional shares. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on June 30, 2025, subject to the satisfaction of customary closing conditions.
Neutral
Zacks Investment Research
2 weeks ago
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.
Neutral
GlobeNewsWire
2 weeks ago
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Positive
Proactive Investors
2 weeks ago
Gilead partners with Kymera to develop novel cancer therapy
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cyclin-dependent kinase 2 (CDK2), a protein that plays a key role in tumor growth. This collaboration aims to accelerate the development and commercialization of a new class of drugs called molecular glue degraders (MDGs), which work by selectively removing the CDK2 protein from cancer cells rather than merely inhibiting its function.
Positive
Reuters
2 weeks ago
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
Neutral
GlobeNewsWire
2 weeks ago
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474
Neutral
Business Wire
2 weeks ago
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors. CDK2-directed MGDs are a new type of d.
Positive
MarketBeat
4 weeks ago
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
Positive
Barrons
1 month ago
Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial
Shares of the biotech Kymera Therapeutics are up 50% since Monday.
Positive
Zacks Investment Research
1 month ago
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
Charts implemented using Lightweight Charts™